IRT vs. RTSM: what’s the difference? What sponsors need to know when choosing clinical trial technology

Author:  Heather Nonnemacher, Director of Services Solutions, Suvoda 

Snapshot: 

• The acronyms IRT and RTSM represent the same core functions: Both support randomization, supply management, patient workflows, and operational oversight.

• Terminology can influence expectations and planning: Historical and regional differences can affect scoping, CRO alignment, and integration assumptions.

• Choosing the right system requires looking past labels: Sponsors should prioritize configurability, supply intelligence, integrations, usability, and reporting.

Clinical trials depend on a network of interconnected systems to manage patients, data, and decisions. Among the most critical, but often least visible, are the systems that control randomization, trial supply, and patient progression. Depending on geography or experience, these systems may be referred to as IRT (Interactive Response Technology) or RTSM (Randomization and Trial Supply Management).

The terms are frequently used interchangeably, yet their origins and implied meanings can still influence how sponsors evaluate solutions today. Understanding where the terminology came from, and what truly matters now, can help sponsors make more confident technology decisions.

Why two terms exist—a brief origin story

IRT came first. Historically, IRT described systems that allowed users like site staff, monitors, or study teams to interact with trial workflows through IVRS (interactive voice response systems via phone), IWRS (interactive web response systems), or later, integrated digital interfaces. The emphasis was on the mode of interaction, not the function.

As the industry matured, the conversation shifted from how users interact with the system toward what the system does. That’s where RTSM emerged: a term that centers the system’s core purpose—randomization and trial supply management.

Location also plays a role. In North America, “IRT” is a common term. In Europe, “RTSM” is often used and can feel more intuitive to teams less familiar with the legacy “IRT” acronym. But in practice? Nearly every modern solution delivers both IRT and RTSM capabilities, just under different labels.

What IRT and RTSM have in common

In practice, today’s IRT and RTSM systems can support the same essential operational functions that keep trials running smoothly. The label matters far less than the capabilities behind it.

At their core, these systems manage randomization, assigning patients to treatment arms within the trial. They also protect the integrity of the study blind, which is an essential requirement for scientific validity and regulatory confidence.

They play an equally important role in drug or investigational product supply management, coordinating depot-to-site shipments, triggering automated resupply, monitoring inventory and expiry, and helping prevent both stock-outs and excess waste.

Modern platforms also support patient, treatment, and visit management throughout the trial lifecycle. This can include screening and enrollment, cohort management, visit scheduling, and dose administration.

Finally, these systems can provide real-time operational visibility. Actionable alerts, key study metrics, and sponsor and CRO oversight tools enable teams to identify issues early and respond quickly. Integration with software such as EDC, eCOA, eConsent, and patient-facing tools further strengthens this visibility by supporting timely, consistent data flow.

Taken together, these capabilities form a sophisticated operational backbone—whether the system is labeled IRT or RTSM.

So, what’s the real difference?

Functionally, there is little distinction. Today’s IRT and RTSM systems generally perform the same core operational roles. The difference lies in historical context and language, usually not core capability.

For sponsors, the more useful question is not whether to choose an IRT or an RTSM, but which vendor offers a solution that best supports the way their trial needs to run.

Five key considerations when choosing the right system

Looking beyond labels, several practical considerations can guide system selection.

• Adaptability is essential. The system should support mid-study changes without unnecessary disruption and accommodate complex, adaptive, or early-phase designs.
• Supply intelligence matters. Sponsors should evaluate whether the system actively optimizes resupply, reduces waste, and maintains continuity across depots and regions.
• Integration readiness increasingly defines operational efficiency. Mature APIs and real-time data flow across EDC, eCOA, eConsent, and patient-facing platforms are now expected.
• The site experience should be carefully assessed. Intuitive workflows can reduce burden and training time, while poorly designed processes can introduce friction and risk.
• Finally, oversight and reporting capabilities shape how confidently sponsors manage their studies. Clear, actionable, near real-time dashboards support better decision-making as conditions evolve.

Trial wisely, starting with clarity

Whether you call it IRT or RTSM, this technology will shape enrollment, randomization, patient flow, supply strategy, and trial oversight. Clear terminology helps, but thoughtful system selection depends on deeper considerations around protocol design, operational needs, and patient experience.

Suvoda’s technology is designed to support complex trial designs with disciplined configuration, customizability, supply accuracy, and operational transparency. We approach randomization and trial supply management not as a standalone tool, but as a critical component of a broader trial ecosystem—one that connects randomization, supply management, and downstream workflows in a controlled and auditable way.

When sponsors, CROs, and sites share a clear understanding of what these systems do—and what they should deliver—they are better positioned to trial wisely.

Authors

Heather Nonnemacher
Director of Services Solutions,
Suvoda